ImmunityBio (IBRX) Shares Outstanding (Weighted Average) (2013 - 2026)
ImmunityBio (IBRX) reported Shares Outstanding (Weighted Average) of $1.0 billion for Q1 2026, up 20.36% year-over-year from $853.2 million in Q1 2025, and up 1478.51% on a QoQ basis from $65.1 million in Q4 2025.
ImmunityBio (IBRX) has 14 years of Shares Outstanding (Weighted Average) data on file, last reported at $1.0 billion in Q1 2026.
- Quarterly Shares Outstanding (Weighted Average) rose 20.36% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 20.36% YoY) and the FY2025 annual result came in at $919.9 million, up 31.92% from the prior year.
- Shares Outstanding (Weighted Average) climbed to $1.0 billion in Q1 2026 per IBRX's latest filing, from $65.1 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $1.0 billion in Q1 2026 and bottomed at $1.6 million in Q1 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $508.6 million (2023), against an average of $515.8 million.
- The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) slumped 97.66%; it then surged 27677.41% in 2023.
- Tracing IBRX's Shares Outstanding (Weighted Average) over 5 years: stood at $9.1 million in 2022, then jumped by 5495.0% to $508.6 million in 2023, then surged by 37.09% to $697.3 million in 2024, then plunged by 90.67% to $65.1 million in 2025, then jumped by 1478.51% to $1.0 billion in 2026.
- Per Business Quant, the three latest IBRX Shares Outstanding (Weighted Average) figures stand at $1.0 billion (Q1 2026), $65.1 million (Q4 2025), and $946.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 132.89 Mn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | 1.03 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | 65.05 Mn |
| Sep 30, 2025 | 946.60 Mn |
| Jun 30, 2025 | 888.22 Mn |
| Mar 31, 2025 | 853.16 Mn |
| Dec 31, 2024 | 697.31 Mn |
| Sep 30, 2024 | 695.90 Mn |
| Jun 30, 2024 | 686.94 Mn |
| Mar 31, 2024 | 672.83 Mn |
| Dec 31, 2023 | 508.64 Mn |
| Sep 30, 2023 | 454.99 Mn |
| Jun 30, 2023 | 432.94 Mn |
| Mar 31, 2023 | 428.38 Mn |
| Dec 31, 2022 | 9.09 Mn |
| Sep 30, 2022 | 1.64 Mn |
| Jun 30, 2022 | 397.99 Mn |
| Mar 31, 2022 | 1.64 Mn |
| Dec 31, 2021 | 389.23 Mn |
| Sep 30, 2021 | 1.64 Mn |
| Jun 30, 2021 | 384.82 Mn |
| Mar 31, 2021 | 1.64 Mn |
| Dec 31, 2020 | 377.07 Mn |
| Sep 30, 2020 | 375.37 Mn |
| Jun 30, 2020 | 372.29 Mn |
| Mar 31, 2020 | 98.47 Mn |
| Dec 31, 2019 | 366.32 Mn |
| Sep 30, 2019 | 98.33 Mn |
| Jun 30, 2019 | 98.59 Mn |
| Mar 31, 2019 | 81.26 Mn |
| Dec 31, 2018 | 79.13 Mn |
| Sep 30, 2018 | 79.20 Mn |
| Jun 30, 2018 | 79.11 Mn |
| Mar 31, 2018 | 79.04 Mn |
| Dec 31, 2017 | 17.72 Mn |
| Sep 30, 2017 | 79.44 Mn |
| Jun 30, 2017 | 81.44 Mn |
| Mar 31, 2017 | 82.14 Mn |
| Dec 31, 2016 | 17.77 Mn |
| Sep 30, 2016 | 82.15 Mn |
| Jun 30, 2016 | 81.96 Mn |
| Mar 31, 2016 | 81.57 Mn |
| Dec 31, 2015 | 17.82 Mn |
| Sep 30, 2015 | 77.84 Mn |
| Jun 30, 2015 | 65.79 Mn |
| Mar 31, 2015 | 61.14 Mn |
| Dec 31, 2014 | 1.85 Mn |
| Sep 30, 2014 | 7.90 Mn |
| Jun 30, 2014 | 7.54 Mn |
| Mar 31, 2014 | 2.88 Mn |
| Dec 31, 2013 | 797,105.00 |